New-Onset Guttate Psoriasis Induced by Durvalumab: Potential Role of Bisoprolol

Durvalumab is an immune checkpoint inhibitor targeting programmed death-ligand 1 (PD-L1), used in the treatment of various advanced cancers. Immune checkpoint inhibitors are associated with immune-related adverse events, mainly affecting the skin and digestive system. Immune-mediated psoriasis has been observed in patients treated with durvalumab. We report a case of new-onset psoriasis in a patient treated concomitantly with durvalumab and bisoprolol, prescribed for a well-differentiated keratinizing squamous cell carcinoma of the upper right lung and for sinus tachycardia, respectively. Topical therapy was effective, and both durvalumab and bisoprolol were continued. The potential role of bisoprolol, a beta-blocker known to induce or exacerbate psoriasis, is discussed. This case highlights the importance of identifying potential drug interactions that may trigger psoriasis.